FIELD: medicine.
SUBSTANCE: invention refers to oncology and can be used to specify steps of advanced cervical cancer. For this, stage of disease as per international gynaecological classification (FIGO) is determined for patient and is referred to Ib-IIa or IIb-IV clinical stage by IL-1β level in blood plasma. At that, Ib-IIa stage is determined by level of IL-1β from 1.330 pg/ml and more, IIb-IV stage is by level IL-1β from 0 pg/ml to 1.330 pg/ml.
EFFECT: invention enables conducting of differential diagnosis of Ib-IIa or IIb-IV cervical cancer in patients.
1 cl, 15 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CERVICAL CANCER STAGING METHOD | 2016 |
|
RU2645111C2 |
| DIAGNOSTIC TECHNIQUE FOR PROGRESSIVE OVARIAN CARCINOMA | 2013 |
|
RU2536272C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR UTERINE CANCER | 2012 |
|
RU2488823C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA OF GRADE III AND MICROINVASIVE CERVICAL CANCER ASSOCIATED WITH HUMAN PAPILLOMA VIRUS | 2019 |
|
RU2735660C1 |
| METHOD FOR DIAGNOSIS OF METASTASES TO LYMPH NODES OF SMALL PELVIS IN PATIENTS WITH RESECTABLE CERVICAL CANCER | 2020 |
|
RU2750769C2 |
| METHOD OF PREDICTION OF PROBABILITY OF CERVICAL CANCER DETECTION BASED ON ROUTINE BLOOD PARAMETERS | 2023 |
|
RU2802395C2 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST | 2012 |
|
RU2483304C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY BLOOD PLASMA CATALASE ACTIVITY TEST | 2012 |
|
RU2483308C1 |
| METHOD FOR REDUCING STIFFNESS OF RED BLOOD CELL MEMBRANE IN PATIENTS SUFFERING FROM CERVICAL CANCER | 2013 |
|
RU2523345C1 |
| METHOD FOR LABORATORY DIAGNOSIS OF STAGES OF HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS C | 2015 |
|
RU2583939C1 |
